Logo

LEO Pharma Signs License and Research Collaboration with Zymeworks to Develop Novel Bispecific Abs

Share this

LEO Pharma Signs License and Research Collaboration with Zymeworks to Develop Novel Bispecific Abs

Shots:

  • Zymeworks to get $5M upfront plus research funding payments from LEO- $231M as milestone to commercialize first candidate & up to $244M for the second candidate along with 20% US sales royalties
  • Zymeworks retains rights to develop non-dermatology molecule using this cytokine receptor pathway where LEO will receive milestone payments and single digit royalties
  • LEO gets WW rights to research- develop & commercialize two bispecific Abs using Zymeworks' Azymetric and EFECT platforms focused on dermatology
  • Azymetric platform helps in transforming monospecific Abs into bispecific Abs- enabling them to bind multiple targets. The EFECT platform is a collection Abs Fc modifications used in modulating Ab-mediated immune response

/ article | Ref: LEO pharma | Image: Appadvice

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions